Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: Relevance for incretin-based diabetes therapy

Neuroendocrinology

Volumn 94, Issue 4, 2011, Pages 291-301

  Waser, Beatrice ^a   Beetschen, Karin ^a   Pellegata, Natalia S ^b   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Diabetes therapy; GIP receptors; GLP 1 receptors; Incretin receptors; Medullary thyroid carcinomas; Thyroid C cells

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CELL DENSITY; CELL HYPERPLASIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPECIES DIFFERENCE; THYROID GLAND; THYROID HYPERPLASIA; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; HUMANS; INCRETINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; THYROID GLAND; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 83655191987     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000330447     Document Type: Article

References (21)

1. Holst JJ: The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439. (Pubitemid 350041474)
2. Irwin N, Flatt PR: Therapeutic potential for GIP receptor agonists and antagonists. Best Pract Res Clin Endocrinol Metab 2009; 23: 499-512.
3. Holst JJ, Vilsboll T, Deacon CF: The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009; 297: 127-136.
4. Kim SJ, Nian C, Widenmaier S, McIntosh CH: Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic bcl-2 gene expression is coordinated by cyclic amp (cAMP) response element binding protein (CREB) and cAMPresponsive CREB coactivator 2. Mol Cell Biol 2008; 28: 1644-1656.
5. Ehses JA, Casilla VR, Doty T, Pospisilik JA, Winter KD, Demuth HU, Pederson RA, McIntosh CH: Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 2003; 144: 4433-4445. (Pubitemid 37204843)
6. Ahren B: Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009; 8: 369-385.
7. Sebokova E, Christ AD, Wang H, Sewing S, Dong JZ, Taylor J, Cawthorne MA, Culler MD: Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency. Endocrinology 2010; 151: 2474-2482.
8. Knop FK, Vilsboll T, Holst JJ: Incretin-based therapy of type 2 diabetes mellitus. Curr Protein Pept Sci 2009; 10: 46-55.
9. Estall JL, Drucker DJ: Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 2006; 12: 1731-1750.
10. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Molck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M: Glucagon-like peptide-1 receptor agonists activate rodent thyroid Ccells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151: 1473-1486.
11. Victoza(liraglutide injection): human relevance of rodent thyroid C-cell tumors. http://www.fda.gov/downloads/Advisory-Committees/ Committees%20MeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM151129. pdf 2009; Accessed October 5, 2010.
12. Korner M, Stockli M, Waser B, Reubi JC: GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48: 736-743. (Pubitemid 47604973)
13. Boorman GA, van Noord MJ, Hollander CF: Naturally occurring medullary thyroid carcinoma in the rat. Arch Pathol 1972; 94: 35-41.
14. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J, Atkinson MJ: Germ-line mutations in p27kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006; 103: 15558-15563. (Pubitemid 44625631)
15. Carlomagno F, Salvatore D, Santoro M, de Franciscis V, Quadro L, Panariello L, Colantuoni V, Fusco A: Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 1995; 207: 1022-1028.
16. Massart C, Gibassier J, Raoul M, Denais A, Maugendre S, Darcel F, Lucas C: Effect of S9788 on the efficiency of doxorubicin in vivo and in vitro in medullary thyroid carcinoma xenograft. Anticancer Drugs 1996; 7: 321-330.
17. Quazzani L, Reubi JC, Volle GE, Lausson S, Pidoux E, Moukhtar MS, Treilhou-Lahille F: Evaluation of somatostatin biosynthesis, somatostatin receptors and tumor growth in murine medullary thyroid carcinoma. Eur J Endocrinol 1994; 131: 522-530. (Pubitemid 24349194)
18. Reubi JC, Waser B: Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996; 67: 644-647. (Pubitemid 26300980)
19. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E: Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991; 64: 567-573.
20. Thorens B: Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641-8645.
21. Asmar M, Holst JJ: Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances. Curr Opin Endocrinol Diabetes Obes 2010; 17: 57-62.